Darling Ingredients
DAR NYSE Agricultural Products & Services Financials FY2016βFY2025
Darling Ingredients' revenue rose 7.4% to $6.1 billion in fiscal 2025. Its operating margin was 4.5%, down from 8.2% a year earlier. Free cash flow was $679 million, up 34.0%. It paid out $35 million in dividends and buybacks, 5% of free cash flow. The diluted share count fell 0.8%.
What Darling Ingredients does
No business description yet.
- Legal name
- DARLING INGREDIENTS INC.
- Fiscal year ends
- January 3, 2026
- Latest annual report
- β
- Accession Β· CIK
- 0000916540-26-000008
0000916540
Revenue and margins
Darling Ingredients had $6.1B of revenue in fiscal 2025, up 7.4% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew β5.0% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $679M in fiscal 2025, 11.1% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Darling Ingredients returned $34.7M to shareholders in fiscal 2025, 5% of free cash flow. The diluted share count fell 0.8%.
Value Darling Ingredients yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
Discounted cash flow
Value per share
β
Adds net cash of β$3.9B and divides by 160.2M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Earnings multiple
Value per share
β
Reference multiples: today 15.2x Β· peers 23.0x Β· sector 24.7x.
Balance sheet
Cash, debt and the ratios that show how comfortably Darling Ingredients can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $68.9M | $127M | $127M | $76.0M | $88.7M |
| Debt incl. finance leases | $1.5B | $3.4B | $4.4B | $4.1B | $4.0B |
| Net debt / EBITDA | 1.2x | 2.3x | 3.0x | 4.1x | 5.0x |
| Debt / equity | 0.5x | 0.9x | 1.0x | 0.9x | 0.8x |
| Interest coverage | 14.3x | 8.2x | 3.7x | 1.8x | 1.2x |
| Current ratio | 1.5x | 1.5x | 1.9x | 1.4x | 1.5x |
| Quick ratio | 0.8x | 0.9x | 1.1x | 0.8x | 1.0x |
| Total assets | $6.1B | $9.2B | $11.1B | $10.1B | $10.3B |
| Total liabilities | $2.8B | $5.3B | $6.4B | $5.6B | $5.5B |
| Shareholders' equity | $3.3B | $3.8B | $4.6B | $4.4B | $4.7B |
| Net debt (β = net cash) | $1.4B | $3.3B | $4.3B | $4.0B | $3.9B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.1M
1 insider
Sold, 12 months
$4.5M
6 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Randall C StueweChairman and CEO, Director | Sold | 5,000 | $68.20 | $0.3M | Form 4 |
| Aug 18, 2026 | Joseph ManziChief Accounting Officer | Sold | 1,000 | $67.27 | $0.1M | Form 4 |
| Aug 17, 2026 | Sandra DudleyEVP Chief Strategy Officer | Sold | 6,474 | $67.87 | $0.4M | Form 4 |
| Aug 14, 2026 | Patrick McNuttEVP Chief Admin Officer | Sold | 8,000 | $67.09 | $0.5M | Form 4 |
| Aug 13, 2026 | Randall C StueweChairman and CEO, Director | Sold | 5,000 | $64.79 | $0.3M | Form 4 |
| Aug 12, 2026 | Randall C StueweChairman and CEO, Director | Sold | 5,000 | $63.26 | $0.3M | Form 4 |
| Aug 10, 2026 | Nicholas James KemphausEVP Gen. Counsel & Secretary | Sold | 1,591 | $63.05 | $0.1M | Form 4 |
| Jul 31, 2026 | Charles L AdairDirector | Bought | 1,000 | $60.97 | $0.1M | Form 4 |
| May 1, 2026 | Joseph ManziChief Accounting Officer | Sold | 3,000 | $63.89 | $0.2M | Form 4 |
| Mar 6, 2026 | Randall C StueweChairman and CEO, Director | Sold | 20,000 | $52.12 | $1.0M | Form 4 |
| Feb 18, 2026 | der Velden Jan vanEVP Int Rendering&Specialties | Sold | 3,000 | $51.29 | $0.2M | Form 4 |
| Feb 17, 2026 | der Velden Jan vanEVP Int Rendering&Specialties | Sold | 20,000 | $51.22 | $1.0M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 7 / 9 | 5 / 9 | 7 / 9 |
| Accruals ratio | β2.5% | β5.3% | β9.8% |
| Altman Z'' | 2.96 | 2.71 | 2.72 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Darling Ingredients DAR | $9.0B | 7.4% | 4.5% | 11.1% | 3.2% | 15.2x | 7 | |
| Ingredion INGR | $6.1B | β2.8% | 14.1% | 7.1% | 16.0% | 10.4x | 8 | Compare β |
| Dole DOLE | $1.3B | 8.2% | 2.4% | 0.0% | 6.3% | β | 6 | Compare β |
| Bunge Global BG | $20.2B | 32.4% | β | β1.3% | 6.1% | 24.1x | 4 | Compare β |
| Archer Daniels Midland ADM | $38.9B | β6.2% | β | 5.2% | 5.2% | 22.0x | 5 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.4B | $3.7B | $3.4B | $3.4B | $3.6B | $4.7B | $6.5B | $6.8B | $5.7B | $6.1B |
| Gross profit | $757M | $787M | $741M | $775M | $883M | $1.2B | $1.5B | $1.6B | $1.3B | $1.5B |
| Operating income | $155M | $169M | $255M | $476M | $431M | $885M | $1.0B | $950M | $468M | $273M |
| Interest expense | $94.2M | $88.9M | $86.4M | $78.7M | $72.7M | $62.1M | $126M | $259M | $254M | $222M |
| Pretax income | $123M | $64.2M | $118M | $380M | $354M | $821M | $894M | $720M | $248M | $61.0M |
| Income tax | $15.3M | β$69.2M | $12.0M | $59.5M | $53.3M | $164M | $147M | $59.6M | β$38.3M | β$9.4M |
| Net income | $102M | $129M | $102M | $313M | $297M | $651M | $738M | $648M | $279M | $62.8M |
| Diluted EPS | $0.62 | $0.77 | $0.60 | $1.86 | $1.78 | $3.90 | $4.49 | $3.99 | $1.73 | $0.39 |
| Diluted shares | 0.17B | 0.17B | 0.17B | 0.17B | 0.17B | 0.17B | 0.16B | 0.16B | 0.16B | 0.16B |
| Cash flow | ||||||||||
| Cash from operations | $391M | $410M | $399M | $363M | $625M | $704M | $814M | $899M | $839M | $1.1B |
| Capital expenditure | $244M | $274M | $322M | $360M | $280M | $274M | $391M | $556M | $333M | $381M |
| Free cash flow | $147M | $136M | $76.7M | $3.1M | $345M | $430M | $422M | $344M | $507M | $679M |
| Depreciation and amortization | $290M | $302M | $321M | $326M | $350M | $316M | $395M | $502M | $504M | $509M |
| Stock-based compensation | $10.3M | $17.6M | $18.8M | $21.0M | $23.2M | $21.8M | $25.0M | $33.2M | $20.9M | $21.8M |
| Acquisitions | $8.5M | $12.1M | $108M | $1.4M | $29.8M | $2.1M | $1.8B | $1.1B | $117M | $0.0M |
| Share buybacks | $5.0M | $0.0M | $0.0M | $19.3M | $55.0M | $168M | $126M | $52.9M | $34.3M | $34.7M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $5.0M | $0.0M | $0.0M | $19.3M | $55.0M | $168M | $126M | $52.9M | $34.3M | $34.7M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $115M | $107M | $107M | $72.9M | $81.6M | $68.9M | $127M | $127M | $76.0M | $88.7M |
| Total debt | $1.8B | $1.7B | $1.7B | $1.7B | $1.5B | $1.5B | $3.4B | $4.4B | $4.1B | $4.0B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.1M | $3.7M | $2.7M | $14.4M | $14.9M | $9.4M | $5.8M |
| Current assets | $893M | $956M | $898M | $917M | $987M | $1.1B | $1.6B | $1.9B | $1.4B | $1.6B |
| Current liabilities | $452M | $560M | $541M | $688M | $675M | $753M | $1.1B | $998M | $1.0B | $1.0B |
| Inventory | $331M | $358M | $341M | $363M | $406M | $458M | $674M | $759M | $577M | $528M |
| Property and equipment, net | $1.5B | $1.6B | $1.7B | $1.8B | $1.9B | $1.8B | $2.5B | $2.9B | $2.7B | $2.8B |
| Total assets | $4.7B | $5.0B | $4.9B | $5.3B | $5.6B | $6.1B | $9.2B | $11.1B | $10.1B | $10.3B |
| Total liabilities | $2.6B | $2.6B | $2.6B | $2.7B | $2.7B | $2.8B | $5.3B | $6.4B | $5.6B | $5.5B |
| Shareholders' equity | $2.0B | $2.2B | $2.3B | $2.6B | $2.9B | $3.3B | $3.8B | $4.6B | $4.4B | $4.7B |
| Margins | ||||||||||
| Gross margin | 22.3% | 21.5% | 21.9% | 23.0% | 24.7% | 26.2% | 23.4% | 24.2% | 22.4% | 24.0% |
| Operating margin | 4.6% | 4.6% | 7.5% | 14.1% | 12.1% | 18.7% | 15.8% | 14.0% | 8.2% | 4.5% |
| EBITDA margin | 13.1% | 12.9% | 17.0% | 23.8% | 21.9% | 25.3% | 21.8% | 21.4% | 17.0% | 12.7% |
| Net margin | 3.0% | 3.5% | 3.0% | 9.3% | 8.3% | 13.7% | 11.3% | 9.5% | 4.9% | 1.0% |
| FCF margin | 4.4% | 3.7% | 2.3% | 0.1% | 9.7% | 9.1% | 6.5% | 5.1% | 8.9% | 11.1% |
| Returns | ||||||||||
| Return on capital | 3.6% | 4.4% | 5.8% | 9.8% | 8.5% | 15.5% | 14.4% | 10.8% | 5.4% | 3.2% |
| Return on capital employed | 3.6% | 3.9% | 5.8% | 10.6% | 9.0% | 17.1% | 15.2% | 10.4% | 4.9% | 3.0% |
| Return on equity | 5.3% | 6.1% | 4.5% | 12.9% | 10.9% | 21.1% | 20.8% | 15.4% | 6.2% | 1.4% |
| Return on assets | 2.2% | 2.7% | 2.1% | 6.1% | 5.4% | 11.1% | 9.6% | 6.4% | 2.6% | 0.6% |
| Growth | ||||||||||
| Revenue growth | 0.0% | 8.0% | β7.5% | β0.7% | 6.2% | 32.7% | 37.8% | 3.9% | β15.8% | 7.4% |
| Net income growth | 30.3% | 25.6% | β21.0% | 208.0% | β5.1% | 119.3% | 13.3% | β12.2% | β56.9% | β77.5% |
| EPS growth | 29.2% | 24.2% | β22.1% | 210.0% | β4.3% | 119.1% | 15.1% | β11.1% | β56.6% | β77.5% |
| FCF growth | β22.8% | β7.6% | β43.7% | β95.9% | 10,932.2% | 24.9% | β1.8% | β18.6% | 47.4% | 34.0% |
| Share count change | 0.1% | 0.9% | 0.7% | 0.3% | β0.7% | β0.1% | β1.8% | β1.1% | β0.6% | β0.8% |
| Financial health | ||||||||||
| Net debt / EBITDA | 3.7x | 3.5x | 2.8x | 2.0x | 1.9x | 1.2x | 2.3x | 3.0x | 4.1x | 5.0x |
| Debt / equity | 0.9x | 0.8x | 0.8x | 0.7x | 0.5x | 0.5x | 0.9x | 1.0x | 0.9x | 0.8x |
| Interest coverage | 1.6x | 1.9x | 3.0x | 6.1x | 5.9x | 14.3x | 8.2x | 3.7x | 1.8x | 1.2x |
| Current ratio | 2.0x | 1.7x | 1.7x | 1.3x | 1.5x | 1.5x | 1.5x | 1.9x | 1.4x | 1.5x |
| Quick ratio | 1.2x | 1.1x | 1.0x | 0.8x | 0.9x | 0.8x | 0.9x | 1.1x | 0.8x | 1.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 7.2% | 7.5% | 9.5% | 10.7% | 7.8% | 5.8% | 6.0% | 8.2% | 5.8% | 6.2% |
| Stock comp / revenue | 0.3% | 0.5% | 0.6% | 0.6% | 0.7% | 0.5% | 0.4% | 0.5% | 0.4% | 0.4% |
| Payouts / FCF | 3.4% | 0.0% | 0.0% | 616.7% | 16.0% | 39.0% | 29.7% | 15.4% | 6.8% | 5.1% |
| Quality scores | ||||||||||
| Piotroski F-score | 7.0 | 6.0 | 5.0 | 7.0 | 7.0 | 8.0 | 7.0 | 7.0 | 5.0 | 7.0 |
| Altman Z'' | 2.3 | 2.3 | 2.5 | 2.8 | 3.0 | 3.8 | 3.0 | 3.0 | 2.7 | 2.7 |
| Accruals ratio | β6.1% | β5.8% | β6.0% | β1.0% | β6.0% | β0.9% | β1.0% | β2.5% | β5.3% | β9.8% |
Source: SEC EDGAR XBRL filings (CIK 0000916540). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.